Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences:
- Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET
- JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET
A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005257/en/
Deciphera Pharmaceuticals Aktie
Einseitige Zustimmung für Deciphera Pharmaceuticals mit mehreren Buy- und keiner Sell-Einschätzung.
Mit einem Kurs von 23.8 € erreicht Deciphera Pharmaceuticals das von der Community anvisierte Kursziel von 24 €.